130 related articles for article (PubMed ID: 19691117)
1. Characterization of polymorph transformations that decrease the stability of tablets containing the WHO essential drug mebendazole.
Brits M; Liebenberg W; de Villiers MM
J Pharm Sci; 2010 Mar; 99(3):1138-51. PubMed ID: 19691117
[TBL] [Abstract][Full Text] [Related]
2. Identification of the mebendazole polymorphic form present in raw materials and tablets available in South Africa.
Liebenberg W; Dekker TG; Lötter AP; de Villiers MM
Drug Dev Ind Pharm; 1998 May; 24(5):485-8. PubMed ID: 9876612
[TBL] [Abstract][Full Text] [Related]
3. Mebendazole crystal forms in tablet formulations. An ATR-FTIR/chemometrics approach to polymorph assignment.
Calvo NL; Kaufman TS; Maggio RM
J Pharm Biomed Anal; 2016 Apr; 122():157-65. PubMed ID: 26874854
[TBL] [Abstract][Full Text] [Related]
4. Intermolecular contacts influencing the conformational and geometric features of the pharmaceutically preferred mebendazole polymorph C.
Martins FT; Neves PP; Ellena J; Camí GE; Brusau EV; Narda GE
J Pharm Sci; 2009 Jul; 98(7):2336-44. PubMed ID: 18855910
[TBL] [Abstract][Full Text] [Related]
5. Analysing the crystal purity of mebendazole raw material and its stability in a suspension formulation.
Agatonovic-Kustrin S; Glass BD; Mangan M; Smithson J
Int J Pharm; 2008 Sep; 361(1-2):245-50. PubMed ID: 18555626
[TBL] [Abstract][Full Text] [Related]
6. Development and in vitro characterization of mebendazole delayed release tablet for colonic drug delivery.
Baviskar D; Rajput A; Bare K; Biranwar Y; Chaudhari H; Narkhede D; Jain D
Pak J Pharm Sci; 2014 Mar; 27(2):249-53. PubMed ID: 24577910
[TBL] [Abstract][Full Text] [Related]
7. Developing a discriminating dissolution test for three mebendazole polymorphs based on solubility differences.
Swanepoel E; Liebenberg W; Devarakonda B; de Villiers MM
Pharmazie; 2003 Feb; 58(2):117-21. PubMed ID: 12641328
[TBL] [Abstract][Full Text] [Related]
8. A comparison of the effect of temperature and moisture on the solid dispersions: aging and crystallization.
Tian B; Zhang L; Pan Z; Gou J; Zhang Y; Tang X
Int J Pharm; 2014 Nov; 475(1-2):385-92. PubMed ID: 25218489
[TBL] [Abstract][Full Text] [Related]
9. Variable-temperature X-ray powder diffraction analysis of the crystal transformation of the pharmaceutically preferred polymorph C of mebendazole.
de Villiers MM; Terblanche RJ; Liebenberg W; Swanepoel E; Dekker TG; Song M
J Pharm Biomed Anal; 2005 Jul; 38(3):435-41. PubMed ID: 15925244
[TBL] [Abstract][Full Text] [Related]
10. Quantitative analysis and evaluation of solid-state stability of mebendazole Forms A and C suspensions by powder X-ray diffraction using the Rietveld method.
Ticona Chambi J; Deris Prado L; Ferreira de Carvalho Patricio B; Ceballos M; Bianco I; Fandaruff C; Antunes Rocha HV; Kuznetsov A; Lucia Cuffini S
Int J Pharm; 2024 Jan; 650():123721. PubMed ID: 38110011
[TBL] [Abstract][Full Text] [Related]
11. Modeling of in-use stability for tablets and powders in bottles.
Waterman KC; Chen L; Waterman P; MacDonald BC; Monahan AP; Scrivens G
Drug Dev Ind Pharm; 2016 Oct; 42(10):1571-8. PubMed ID: 27050806
[TBL] [Abstract][Full Text] [Related]
12. Characterization of solid-state forms of mebendazole.
Kumar S; Chawla G; Sobhia ME; Bansal AK
Pharmazie; 2008 Feb; 63(2):136-43. PubMed ID: 18380400
[TBL] [Abstract][Full Text] [Related]
13. Quality evaluation of generic drugs by dissolution test: changing the USP dissolution medium to distinguish between active and non-active mebendazole polymorphs.
Swanepoel E; Liebenberg W; de Villiers MM
Eur J Pharm Biopharm; 2003 May; 55(3):345-9. PubMed ID: 12754010
[TBL] [Abstract][Full Text] [Related]
14. Analysis of mebendazole polymorphs by Fourier transform IR spectrometry using chemometric methods.
Aboul-Enein HY; Bunaciu AA; Fleschin S
Biopolymers; 2002; 67(1):56-60. PubMed ID: 11842414
[TBL] [Abstract][Full Text] [Related]
15. Mebendazole mesylate monohydrate: a new route to improve the solubility of mebendazole polymorphs.
de Paula K; Camí GE; Brusau EV; Narda GE; Ellena J
J Pharm Sci; 2013 Oct; 102(10):3528-38. PubMed ID: 23897162
[TBL] [Abstract][Full Text] [Related]
16. Role of the electrokinetic properties on the stability of mebendazole suspensions for veterinary applications.
Cózar-Bernal MJ; Gallardo V; Sáez-Fernández E; Holgado MA; Alvarez-Fuentes J; Fernández-Arévalo M; Arias JL
Int J Pharm; 2010 Jun; 393(1-2):161-6. PubMed ID: 20435113
[TBL] [Abstract][Full Text] [Related]
17. Comparative stability of repackaged metoprolol tartrate tablets.
Yang Y; Gupta A; Carlin AS; Faustino PJ; Lyon RC; Ellison CD; Rothman B; Khan MA
Int J Pharm; 2010 Jan; 385(1-2):92-7. PubMed ID: 19879937
[TBL] [Abstract][Full Text] [Related]
18. Effect of milling conditions on solid-state amorphization of glipizide, and characterization and stability of solid forms.
Xu K; Xiong X; Zhai Y; Wang L; Li S; Yan J; Wu D; Ma X; Li H
J Pharm Biomed Anal; 2016 Sep; 129():367-377. PubMed ID: 27454088
[TBL] [Abstract][Full Text] [Related]
19. Study of accelerated storage conditions affecting physical characteristics, in-vitro dissolution and stability of bioadhesive containing tablets.
Hosny EA
Boll Chim Farm; 1999 Jun; 138(6):243-8. PubMed ID: 10464972
[TBL] [Abstract][Full Text] [Related]
20. Anthelmintic efficacy of mebendazole depends on the molecular polymorph.
Evans AC; Fincham JE; Dhansay MA; Liebenberg W
S Afr Med J; 1999 Nov; 89(11):1118. PubMed ID: 10599275
[No Abstract] [Full Text] [Related]
[Next] [New Search]
